Latest & greatest articles for lovastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lovastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lovastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lovastatin

1. Lovastatin

Lovastatin Top results for lovastatin - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lovastatin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Coronary angiographic changes wit... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1993 ) Volume: 119 , Issue: 10 , Pages: 969-976 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To assess the effects of lipid-lowering therapy with lovastatin on coronary (...) coronary artery disease. INTERVENTION: A cholesterol-lowering diet and either lovastatin, 80 mg/day, or placebo. OUTCOME: Per-patient change in percent diameter stenosis as determined by quantitative coronary angiography (primary end point). Global change score, based on the consensus of blinded expert readers regarding angiographic change (secondary endpoint). RESULTS: Lovastatin lowered total cholesterol level by 32%, low-density lipoprotein cholesterol by 38%, and the apolipoprotein B by 26

Annals of Internal Medicine2013

3. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group [see comments]

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group [see comments] Coronary angiographic changes wit... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1993 ) Volume: 119 , Issue: 10 , Pages: 969-976 Find this paper at: Abstract OBJECTIVE: To assess the effects of lipid-lowering therapy with lovastatin (...) ) and angiographically defined coronary artery disease. INTERVENTION: A cholesterol-lowering diet and either lovastatin, 80 mg/day, or placebo. OUTCOME: Per-patient change in percent diameter stenosis as determined by quantitative coronary angiography (primary end point). Global change score, based on the consensus of blinded expert readers regarding angiographic change (secondary endpoint). RESULTS: Lovastatin lowered total cholesterol level by 32%, low-density lipoprotein cholesterol by 38%, and the apolipoprotein

Annals of Internal Medicine2013

4. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study.

Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Lovastatin (mevinolin) in the tre... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1987 ) Volume: 107 , Issue: 5 , Pages: 609-615 PubMed: Available from or Find this paper at: Abstract STUDY OBJECTIVE: To evaluate the efficacy and tolerability of lovastatin under controlled (...) of placebo or lovastatin 5 to 40 mg twice daily or 20 to 40 mg once daily in the evening, during three consecutive 6-week periods. MEASUREMENTS AND MAIN RESULTS: The mean reductions in total plasma cholesterol and low-density lipoprotein cholesterol across the dosage ranges were 14% to 34% and 17% to 39%, respectively (p compared with zero and placebo less than 0.01). High-density lipoprotein cholesterol and apolipoproteins AI and AII rose slightly. Apolipoprotein B fell substantially at the higher

Annals of Internal Medicine2013

5. Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data

Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data Armstrong E P, Zachry W M, Malone D C Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of simvastatin and lovastatin/extended-release niacin to achieve low-density lipoprotein (LDL) and high-density Lipoprotein (HDL) cholesterol goals. The simvastatin pathway started with 20 mg/day and was titrated monthly to a maximum dosage of 80

NHS Economic Evaluation Database.2004

6. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein.

Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. 12876093 2003 07 23 2003 07 28 2016 10 17 1538-3598 290 4 2003 Jul 23 JAMA JAMA Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. 502-10 To enhance the effectiveness of diet in lowering cholesterol, recommendations of the Adult Treatment Panel III of the National Cholesterol Education Program emphasize diets low (...) (SE) age of 59 (1) years and body mass index of 27.6 (0.5), recruited from a Canadian hospital-affiliated nutrition research center and the community. Participants were randomly assigned to undergo 1 of 3 interventions on an outpatient basis for 1 month: a diet very low in saturated fat, based on milled whole-wheat cereals and low-fat dairy foods (n = 16; control); the same diet plus lovastatin, 20 mg/d (n = 14); or a diet high in plant sterols (1.0 g/1000 kcal), soy protein (21.4 g/1000 kcal

JAMA2003

7. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial.

Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. 9917116 1999 01 27 1999 01 27 2016 10 17 0098-7484 281 2 1999 Jan 13 JAMA JAMA Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. 137-44 Heterozygous familial hypercholesterolemia (HeFH) is a common disorder associated with early coronary artery disease, especially in men. The age (...) at which drug therapy should be started is still controversial, as is the use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). To assess the lipid-lowering efficacy, biochemical safety, and effect on growth and sexual development of lovastatin in adolescent boys with HeFH. One-year, double-blind, placebo-controlled, balanced, 2-period, 2-arm randomized trial. In the first period (24 weeks), lovastatin was increased at 8 and 16 weeks and the dosage remained stable during

JAMA1999

8. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. 9613910 1998 06 10 1998 06 10 2016 10 17 0098-7484 279 20 1998 May 27 JAMA JAMA Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. 1615-22 Although (...) cholesterol-reducing treatment has been shown to reduce fatal and nonfatal coronary disease in patients with coronary heart disease (CHD), it is unknown whether benefit from the reduction of low-density lipoprotein cholesterol (LDL-C) in patients without CHD extends to individuals with average serum cholesterol levels, women, and older persons. To compare lovastatin with placebo for prevention of the first acute major coronary event in men and women without clinically evident atherosclerotic

JAMA1998

9. Replacing lovastatin with pravastatin: effect on serum lipids and costs

Replacing lovastatin with pravastatin: effect on serum lipids and costs Replacing lovastatin with pravastatin: effect on serum lipids and costs Replacing lovastatin with pravastatin: effect on serum lipids and costs Korman L, Borysiuk L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology Pravastatin. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population Patients being treated with lovastatin, with an average age of 66 years. Setting Primary care. The economic study was carried out in Connecticut, USA. Dates to which data relate Costs mainly related to 1993 and were expressed in 1995 prices. Effectiveness data were collected up until October 1993. Source of effectiveness data

NHS Economic Evaluation Database.1995

10. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy

Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy Schrott H G, Stein E A, Dujovne C A, Davidson M H, Goris G B, Oliphant T H, Phillips J C (...) , Shawaryn G G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Use of low-dose combination of drug regimens of colestipol and lovastatin in reducing low-density lipoprotein (LDL) cholesterol levels. Type of intervention Secondary

NHS Economic Evaluation Database.1995

11. Hypercholesterolemia in postmenopausal women. Metabolic defects and response to low-dose lovastatin.

Hypercholesterolemia in postmenopausal women. Metabolic defects and response to low-dose lovastatin. 8295321 1994 03 02 1994 03 02 2016 10 17 0098-7484 271 6 1994 Feb 09 JAMA JAMA Hypercholesterolemia in postmenopausal women. Metabolic defects and response to low-dose lovastatin. 453-9 To determine the metabolic mechanisms underlying hypercholesterolemia in postmenopausal women and to determine whether a low dose of lovastatin will correct this abnormality. In the first part of the study (...) , turnover rates of autologous low-density lipoprotein (LDL) were measured in hypercholesterolemic and control women. In the second part, hypercholesterolemic women participated in a placed-controlled, randomized, double-blind study using lovastatin as the therapeutic agent. The General Clinical Research Center of the University of Texas Southwestern Medical Center, Dallas, utilizing inpatient and outpatient facilities, and the Veterans Affairs Medical Center, Dallas, Tex. For the LDL turnover study, 26

JAMA1994

12. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group.

Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. 7935702 1994 11 17 1994 11 17 2016 11 23 0028-4793 331 20 1994 Nov 17 The New England journal of medicine N. Engl. J. Med. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. 1331-7 Experimental and clinical observations suggest that lowering serum lipid levels may reduce the risk of restenosis after coronary angioplasty. We (...) report the results of a prospective, randomized, double-blind trial evaluating whether lowering lipid levels with lovastatin can prevent or delay restenosis after angioplasty. Seven to 10 days before angioplasty, we randomly assigned eligible patients to receive lovastatin (40 mg orally twice daily) or placebo. Patients who underwent successful, complication-free, first-time angioplasty of a native vessel (the index lesion) continued to receive therapy for six months, when a second coronary angiogram

NEJM1994

13. Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia.

Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia. Efficacy and tolerability of lova... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1993 ) Volume: 118 , Issue: 11 , Pages: 850-855 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia. DESIGN (...) : The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks. SETTING: Ambulatory patients recruited by 362 participating centers throughout the United States. PATIENTS: Women (n = 3390) from the total cohort of 8245 volunteers. MEASUREMENTS: Plasma total, low-density lipoprotein

Annals of Internal Medicine1993

14. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia.

The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. 8464431 1993 05 04 1993 05 04 2013 11 21 0028-4793 328 17 1993 Apr 29 The New England journal of medicine N. Engl. J. Med. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. 1213-9 A diet low in saturated fat and cholesterol is the standard initial treatment for hypercholesterolemia. However, little quantitative (...) information is available about the efficacy of dietary therapy in clinical practice or about the combined effects of diet and drug therapy. One hundred eleven outpatients with moderate hypercholesterolemia were treated at five lipid clinics with the National Cholesterol Education Program Step 2 diet (which is low in fat and cholesterol) and lovastatin (20 mg once daily), both alone and together. A diet high in fat and cholesterol and a placebo identical in appearance to the lovastatin were used

NEJM1993

15. Lovastatin efficacy in reducing low-density lipoprotein cholesterol levels on high- vs low-fat diets.

Lovastatin efficacy in reducing low-density lipoprotein cholesterol levels on high- vs low-fat diets. 1992214 1991 03 13 1991 03 13 2016 10 17 0098-7484 265 8 1991 Feb 27 JAMA JAMA Lovastatin efficacy in reducing low-density lipoprotein cholesterol levels on high- vs low-fat diets. 997-1001 The effectiveness of lovastatin was compared with both a high-fat vs low-fat diet. Hypercholesterolemic subjects were studied under metabolic ward conditions for diet periods of 3 weeks while receiving (...) lovastatin (40 mg/d) or placebo. Multiple lipoprotein levels were measured during the final week of each diet period. Nineteen subjects completed the study on the high-fat (43% of kilojoules) diet and 16 on the low-fat (25% of kilojoules) diet. Lovastatin reduced total cholesterol by 23% and low-density lipoprotein cholesterol by 30%, compared with placebo on both diets, with no significant diet-drug interaction. High-density lipoprotein cholesterol was raised by 7% to 8% on the diet regimens. Addition

JAMA1991

16. Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy.

Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy. 2232062 1990 12 26 1990 12 26 2016 10 17 0098-7484 264 21 1990 Dec 05 JAMA JAMA Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy. 2759-63 A common pattern of dyslipidemia is elevated levels of plasma triglyceride, borderline high total (...) cholesterol, reduced high-density lipoprotein, and increased apolipoprotein B. This pattern of dyslipidemia frequently is associated with premature coronary heart disease. Nicotinic acid is the drug of first choice for this pattern. In this study, gemfibrozil and lovastatin were compared for their effects on the overall lipoprotein profile in 13 men with this type of dyslipidemia. Both drugs significantly reduced very-low-density lipoprotein and intermediate-density lipoprotein cholesterol levels

JAMA1990

17. Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia.

Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia. 2810673 1989 12 21 1989 12 21 2016 10 17 0098-7484 262 22 1989 Dec 08 JAMA JAMA Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia. 3148-53 This study compared lovastatin and gemfibrozil therapy for effects on lipid and lipoprotein levels in 22 normolipidemic patients with reduced high-density lipoprotein cholesterol levels. Most patients had coronary (...) heart disease. A randomized, crossover design consisted of two drug phases (lovastatin and gemfibrozil) alternating with placebo. Lovastatin reduced total and low-density lipoprotein cholesterol and apolipoprotein B levels by 28%, 34%, and 24%, respectively. These were unaffected by gemfibrozil. Both drugs reduced very low-density lipoprotein and intermediate-density lipoprotein cholesterol levels by 30% to 40%. Both caused small but significant increases in high-density lipoprotein cholesterol

JAMA1989

18. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus.

Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. 3422105 1988 02 02 1988 02 02 2013 11 21 0028-4793 318 2 1988 Jan 14 The New England journal of medicine N. Engl. J. Med. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. 81-6 Coronary heart disease is an important cause of death in patients with non-insulin-dependent diabetes mellitus (NIDDM) and is particularly common in diabetic populations that have relatively high (...) levels of plasma cholesterol. To determine whether plasma cholesterol levels in patients with NIDDM could be reduced by drug therapy, we assessed the effect of lovastatin, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, in a randomized double-blind placebo-controlled manner in 16 white patients with NIDDM and mild to moderate elevations of plasma cholesterol. Lovastatin (20 mg twice daily) or a placebo was given for four weeks, during which blood glucose concentrations remained

NEJM1988

19. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group III.

A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group III. 2898027 1988 07 28 1988 07 28 2016 10 17 0098-7484 260 3 1988 Jul 15 JAMA JAMA A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group III. 359-66 This study compares lovastatin and cholestyramine resin therapy in patients with severe primary hypercholesterolemia. Two hundred sixty (...) -four patients on lipid-lowering diets were randomized equally to receive 12 g of cholestyramine resin, 20 mg of lovastatin, or 40 mg of lovastatin, each twice a day. The mean reductions among the three groups after 12 weeks' treatment in levels of total plasma cholesterol (-17%, -27%, and -34%, respectively) and low-density lipoprotein cholesterol (-23%, -32%, and -42%, respectively) and the median reductions in apolipoprotein B levels (-21%, -28%, and -33%, respectively) were all significantly

JAMA1988

20. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II.

Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II. 3534333 1986 12 16 1986 12 16 2016 10 17 0098-7484 256 20 1986 Nov 28 JAMA JAMA Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II. 2829-34 Lovastatin (mevinolin), a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, was investigated in a double-blind, placebo (...) -controlled multicenter study of 101 patients with nonfamilial primary hypercholesterolemia. Dosages varied from 10 to 80 mg/d in single or divided doses. Patients receiving 40 mg twice a day experienced mean total and low-density lipoprotein cholesterol reductions of 32% and 39%, respectively. High-density lipoprotein cholesterol levels tended to rise slightly and plasma triglyceride levels were moderately decreased. Adverse effects attributable to lovastatin were infrequent and no patient was withdrawn

JAMA1986